Name: 原发性胶质母细胞瘤辅助放疗同意差异的人群研究
Creator: 千方医数集科研发现管道
License: CC BY 4.0

基本信息

模态

表格

大小

0.000050171 GB

许可

CC BY 4.0

创建/更新时间

2025-02-07

版本

v2

资源简介

原发性胶质母细胞瘤辅助放疗同意差异的人群研究

【数据集背景】

本数据集源站标题为《Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study》。配套论文《Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study》发表于 Expert Review of Anticancer Therapy（2025），DOI：10.1080/14737140.2025.2464935。项目资助方：This paper was not funded.。源站首次发布：2025-02-13。

【数据内容】

源站原始描述：Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM. Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relatio…

【数据结构与技术规格】

文件数 2 个，合计 50.17 KB。iery_a_2464935_sm5114.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，25.05 KB。iery_a_2464935_sm5113.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，25.12 KB。数据集 DOI：10.6084/m9.figshare.28367568.v2。

【主题与分类】

源站学科分类：Medicine、Microbiology、Biotechnology、Immunology、Biological Sciences not elsewhere classified、Cancer。主题标签：Glioblastoma、radiotherapy、refusal、SEER、prognosis。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Disparities_in_Consent_to_Adjuvant_Radiotherapy_in_Primary_Glioblastoma_a_population-based_study/28367568

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study. Taylor & Francis. Miao, Wang; Yang, Liu; Li, Jinhu; Yan, Xia; Lu, Ying; Yang, Xin

【使用注意】

· 源站最后修改于 2025-03-02，引用时请注意版本时效。

原始链接

https://figshare.com/articles/dataset/Disparities_in_Consent_to_Adjuvant_Radiotherapy_in_Primary_Glioblastoma_a_population-based_study/28367568

访问原始数据

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付，我们提供全链路闭环服务，让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持？联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务（收技术服务费，非数据销售）

暂未开放

当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取（Figshare）

源站标题：Disparities in consent to adjuvant radiotherapy in primary glioblastoma: a population-based study
DOI：10.6084/m9.figshare.28367568.v2
发布日期：2025-02-13
文件数：2 个
文件总体积：50.17 KB
源站页面：https://tandf.figshare.com/articles/dataset/Disparities_in_Consent_to_Adjuvant_Radiotherapy_in_Primary_Glioblastoma_a_population-based_study/28367568

命令行下载

curl -L -o "iery_a_2464935_sm5114.docx" "https://ndownloader.figshare.com/files/52196100"
curl -L -o "iery_a_2464935_sm5113.docx" "https://ndownloader.figshare.com/files/52196103"

文件清单

iery_a_2464935_sm5114.docx（25.05 KB）
iery_a_2464935_sm5113.docx（25.12 KB）

文件总体积 50.17 KB（源站 API 实测）。

数据说明

Despite adjuvant external beam radiation therapy (EBRT) has long been the standard treatment for glioblastoma (GBM), a significant subset of patients chooses to refuse it. We aimed to investigate the factors influencing EBRT refusal in GBM.
Patients with GBM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Both univariable and multivariable logistic regression analyses were employed to evaluate the adjusted odds ratios (aOR) for the refusal of EBRT in relation to various clinical and demographic characteristics.
Among the 29,994 patients analyzed, 675 (2.3%) opted to refuse adjuvant EBRT. Patients aged ≥ 55 years (55–64: aOR 1.63, 95% CI 1.04–2.61, p = 0.03; 65–74: aOR 1.80, 95% CI 1.17–2.87, p = 0.009; 75+: aOR 2.01, 95% CI 1.28–3.24, p = 0.002), being single (aOR 1.68, 95% CI 1.19–2.35, p = 0.002), with a household income of $55,000 to $64,999 (aOR 1.94, 95% CI 1.24–3.07, p = 0.004), and not undergoing chemotherapy (aOR 114, 95% CI 80.2–170.2, p This study underscores the necessity for targeted communication strategies by physicians regarding the benefits of adjuvant EBRT.